Articles from Neuronetics

Advancing mental health treatment through innovative research, offering insights on symptom improvement and clinical tools

Data selected for oral presentation reinforce previous findings on safety and efficacy

Policy update increases access for millions covered by HCSC BlueCross BlueShield policies

BlueCross BlueShield of North Carolina and Louisiana Medicaid Increase Coverage for Patients with Depression

Upgrades improve communication, streamline data management, and strengthen security

NeuroStar Is More Than Halfway to Achieving Its Five-Year Goal of Saving Thousands of Lives

Celebrating milestones in patient care and practice enhancement through NeuroStar’s innovative training facility

New initiative aims to provide information and resources for teen mental health amidst rising public health concerns

Coverage criteria consistent with recent FDA clearance for NeuroStar TMS

NeuroStar, the first and only TMS treatment cleared for adolescents, now covered by Medi-Cal

Updated criteria post-FDA clearance for NeuroStar TMS benefit youth mental health

The first and only TMS company to establish comprehensive standards for patient care and responsiveness in the mental health industry

Early prediction of nonresponse abstract selected for oral presentation as a prestigious Top 4 Abstract at CTMSS 2024

Policy change comes quickly after FDA clearance for NeuroStar TMS use in ages 15 and older

The Company is highlighting stories from adolescents with major depressive disorder on the heels of groundbreaking FDA clearance

Lack of early symptom improvement is not predictive of final responder status

NeuroStar is the first and only TMS therapy cleared as an adjunct treatment for patients ages 15 and older

MALVERN, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQSTIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced an expanded commercial partnership with Transformations Care Network ("TCN"), one of the nation's largest mental health care providers. Under the new agreement, Neuronetics will be the exclusive supplier of new transcranial magnetic stimulation (TMS) equipment to TCN, increasing its NeuroStar TMS footprint and availability to patients.

Advancements provide workflow efficiencies for NeuroStar® TMS providers

Criteria Change Reduces Requirements for Treatment Accessibility

New accessory for NeuroStar TMS reduces patient setup steps and improves efficiency for providers

Technological advances reduce time and increase efficiency for MDD treatment

New updates designed to advance practice efficiency and patient outcomes

Policy Updates from Magellan and Two Additional Payors Increase Access for 3.2 Million Covered Lives

Findings confirm strong correlation between the number of TMS treatment sessions completed and improvement in MDD

Portal provides resources to raise awareness around mental health and suicide prevention

Award Acknowledges Excellence in Digital Marketing Efforts

New automated features elevate the standard of care for NeuroStar® Advanced Therapy practices

Policy Updates Impact Nationwide Commercial Plans for 16.8 Million Covered Lives

First International Approval for Expanded Indication and Certification for MT Cap and D-Tect™ Technologies

Award Recognizes Efforts to Raise Awareness Around Non-Drug Depression Treatment

The Company expands technology for patients with obsessive-compulsive disorder

Lower Medication Requirement Helps Depression Patients Obtain Treatment Sooner

Lowest satisfaction among medication users, highest for users of non-drug solution TMS Therapy

The Company is recognized for its commitment to employees’ well-being

Achievement demonstrates Company’s commitment to rigorous standards for safe and effective products

Data highlights the Company’s commitment to advancing TMS and improving patient outcomes

Campaign features patients’ experiences to support others with depression

Strategic role strengthens NeuroStar® Advanced Therapy commercialization team

UHC Medicare Advantage plans in NGS states expand access via NPPs

BlueCross BlueShield of Mississippi Latest to Allow Non-Physician Practitioners to Prescribe TMS

Fifth FDA clearance in less than two years offers greater connectivity and flexibility to improve the patient and provider experience

Award recognizes NeuroStar for its significant contributions toward patient wellbeing

United HealthCare Optum Reduces Barriers to TMS Eligibility for Depression Patients

Company Launches a New Educational Campaign For Providers

Poster Session Highlights the Strong Dose-Response Relationship and the Importance of Treating Beyond 30 Treatments With NeuroStar Advanced Therapy

New Senior Leadership Role Will Streamline Alignment of All Company Revenue-Generating Functions

NGS MAC Allows Non-Physician Practitioners with Autonomy to Prescribe TMS

Peer-reviewed publication shows NeuroStar TMS as an effective non-drug treatment for depression with comorbid anxiety

NeuroStar’s technology once again recognized as an effective non-drug treatment for patients

Enhancements further establish the Company’s leadership position as the top transcranial magnetic stimulation therapy

NeuroStar technology is acknowledged for its innovation and accessibility as a non-drug treatment for mental health

Published and Proposed Medicare Coverage through CGS and NGS MACs Will Reduce Number of Medication Trials, Leading to Increased Eligibility for TMS